A detailed history of China Universal Asset Management Co., Ltd. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 9,232 shares of AXSM stock, worth $898,919. This represents 0.09% of its overall portfolio holdings.

Number of Shares
9,232
Previous 5,580 65.45%
Holding current value
$898,919
Previous $449,000 84.63%
% of portfolio
0.09%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$78.93 - $95.84 $288,252 - $350,007
3,652 Added 65.45%
9,232 $829,000
Q2 2024

Jul 19, 2024

SELL
$65.72 - $80.5 $231,531 - $283,601
-3,523 Reduced 38.7%
5,580 $449,000
Q1 2024

Apr 29, 2024

BUY
$69.39 - $97.64 $251,746 - $354,237
3,628 Added 66.26%
9,103 $726,000
Q4 2023

May 21, 2024

SELL
$57.42 - $83.61 $208,319 - $303,337
-3,628 Reduced 39.85%
5,475 $435,000
Q4 2023

Jan 23, 2024

BUY
$57.42 - $83.61 $245,240 - $357,098
4,271 Added 354.73%
5,475 $436,000
Q3 2023

May 21, 2024

BUY
$69.25 - $82.21 $43,835 - $52,038
633 Added 110.86%
1,204 $84,000
Q3 2023

Oct 30, 2023

BUY
$69.25 - $82.21 $43,835 - $52,038
633 Added 110.86%
1,204 $84,000
Q2 2023

May 21, 2024

SELL
$58.41 - $90.35 $1,051 - $1,626
-18 Reduced 3.06%
571 $41,000
Q2 2023

Jul 27, 2023

SELL
$58.41 - $90.35 $1,051 - $1,626
-18 Reduced 3.06%
571 $41,000
Q1 2023

May 21, 2024

BUY
$58.39 - $75.0 $8,641 - $11,100
148 Added 33.56%
589 $36,000
Q1 2023

Apr 27, 2023

BUY
$58.39 - $75.0 $8,641 - $11,100
148 Added 33.56%
589 $36,000
Q4 2022

May 21, 2024

SELL
$39.94 - $79.72 $345,960 - $690,534
-8,662 Reduced 95.16%
441 $34,000
Q4 2022

Jan 31, 2023

BUY
$39.94 - $79.72 $2,556 - $5,102
64 Added 16.98%
441 $34,000
Q3 2022

Oct 21, 2022

BUY
$36.06 - $69.85 $13,594 - $26,333
377 New
377 $17,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $4.18B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.